Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 3 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 6Lymphoma 4Lymphoma, Non-Hodgkin 3Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, B-Cell 2Tumor Lysis Syndrome 1Recurrence 1Neoplasm, Residual 1Leukemia 1Disease 1Chromosome 17 deletion 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × obinutuzumab × Clear all
NCT06191744 2026-05-06

EPCOREâ„¢FL-2

Genmab

Phase 3 Recruiting
1,095 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡